MedTrace Logo

A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

NCT01023230 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-04-16

No results posted yet for this study

Summary

The purpose of this study is to determine if DV-601, an investigational, therapeutic vaccine will be well-tolerated and induce hepatitis B virus (HBV)-specific virological and immunological responses in chronic hepatitis B (CHB) patients.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

DV-601

Six injections of DV-601 administered over a period of 12 weeks.

DRUG

Entecavir

Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.

Sponsors & Collaborators

  • Dynavax Technologies Corporation

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01023230 on ClinicalTrials.gov